CytoDyn (CYDY) Deferred Taxes (2018 - 2019)

CytoDyn's (CYDY) quarterly Deferred Taxes came in at $26919.0 in Q2 2019, down 99.05% on a QoQ basis from $2.8 million in Q4 2018.

CytoDyn (CYDY) Deferred Taxes (2018 - 2019) Analysis & Trends

CytoDyn (CYDY) has 2 years of Deferred Taxes data on file, last reported at $26919.0 in Q2 2019.

Quarterly Deferred Taxes changed N/A year-over-year to $26919.0 in Q2 2019, while the trailing twelve-month figure through May 2020 was $26919.0 (down 99.06% YoY) and the FY2019 annual result came in at -$2.8 million, changed N/A from the prior year.
Deferred Taxes eased to $26919.0 in Q2 2019, from $2.8 million in the prior quarter.
In the past five years, Deferred Taxes ranged from a high of $2.8 million in Q4 2018 to a low of $26919.0 in Q2 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-69.70 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	194.40 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-137,876.64
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	2.66 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	CytoDyn	258.01 Mn	258.01 Mn	-	-

Download Data

Date	Value
May 31, 2019	26,919.00
Nov 30, 2018	2.83 Mn